Prenetics raises 2026 guidance on IM8 supplement growth By Investing.com

Prenetics reported preliminary Q1 revenue of $36.0 million, raised 2026 IM8 revenue guidance to $190 million-$210 million from $180 million-$200 million, and said Q2 total revenue should reach $46 million-$48 million. IM8 revenue rose 23.1% sequentially to $33.8 million, gross margin improved to about 64%, and the company ended the quarter with $56.0 million in cash before later adding $41.3 million from digital asset sales. The company also executed about $19 million of a $40 million buyback program and announced new product launches plus leadership and partnership updates.

Analysis

This is less a one-quarter story than a financing-and-distribution reset. By converting a volatile balance sheet asset into cash and pairing it with repurchases, management is implicitly telling the market the equity is the cheapest currency in the capital structure; that usually works best when operating momentum is still compounding and near-term dilution risk is low. The second-order effect is that PRE should trade more like a consumer brand roll-up with optionality than a crypto-adjacent balance sheet name, which can broaden its buyer base and compress the discount rate if execution stays clean.

The real inflection is margin durability. Gross margin expansion at the brand level matters more than headline revenue because it creates room for reinvestment in creator/athlete-driven customer acquisition without immediately leaking through to EBITDA. The key question over the next 1-2 quarters is whether international mix and new-product launches raise lifetime value faster than paid-media costs; if CAC inflation shows up, the market will rapidly re-rate this as a low-quality growth story despite the current momentum.

Competitively, the biggest winners are adjacent premium wellness brands that can piggyback on the category expansion, while legacy supplement players with weaker digital acquisition engines may face share pressure as PRE uses a cleaner narrative, celebrity distribution, and buybacks to defend attention. The contrarian risk is that the market is extrapolating a straight-line growth curve from a still-small base: at sub-$300M market cap, any stumble in launch timing, channel mix, or inventory discipline can produce violent multiple compression because expectations are now ahead of current earnings power.

Catalyst sequencing matters: the next 30-60 days should be driven by flow and buyback support, but the more important test is the Q4 product slate and whether management can prove that incremental categories monetize at similar margins. If those launches land, the stock can justify a premium multiple; if not, this looks like a momentum-led rerating that stalls once the near-term financial engineering is fully discounted.

Key Decisions for Investors

• Long PRE into pullbacks over the next 1-3 weeks, using the buyback as a downside absorber; target a re-rate toward the analyst range if Q2 commentary confirms sustained international demand, but keep a tight stop if gross margin or CAC trends soften.
• Buy PRE call spreads 2-3 months out to express upside from the product-launch and buyback catalyst while limiting downside if the momentum trade exhausts; best structure is a modestly out-of-the-money spread with 2:1 or better reward/risk.
• Pair trade: long PRE / short a weaker public supplement or wellness peer with slower digital growth and less balance-sheet flexibility over the next quarter; this isolates execution and distribution execution quality rather than category beta.
• Trim or avoid chasing PRE after large single-day gaps; the stock is now sensitive to any miss in launch timing or margin, so add only on volatility compression or post-event confirmation.
• If Q4 launches and international mix show up as expected, add on strength rather than waiting for a cheaper entry—the setup could force a multiple reset higher as investors price in a self-funded growth engine.